Navigation Links
Scientists win $2 million to study new pathway in development and maintenance of lymphoma
Date:3/30/2012

JUPITER, FL, March 30, 2012 The National Institutes of Health has awarded The Scripps Research Institute $2 million to study the role of a pathway in the development and maintenance of B-cell lymphoma, a type of cancer that begins in immune system and turns normal disease fighting cells into cancers. The disease affects immune cells known as lymphocytes, which are part of our white blood cells.

John Cleveland, PhD, chair of the Department of Cancer Biology on the Scripps Florida campus, will be the principal investigator for the new five-year study.

B-cell lymphomas tend to occur in older patients and in those people whose immune system has been compromised. It is one of the most common blood cancers in the United States and kills about 20,000 Americans each year.

The new project will focus on the role of Myc oncoproteinsthe products of Myc oncogeneswhich are activated in over half of all human tumor types. Myc oncoproteins accelerate the rate of cell growth, which increases the risk of acquiring additional mutations that allow a premalignant cell to develop into a full-blown tumor. In this project, the Cleveland lab will investigate the role of a pathway that controls the destruction of a class of messenger RNAs (mRNAs) that encode proteins that regulate the development and maintenance of tumors.

"This grant allows us to focus on a new pathway that is controlled by Myc that we think is suitable to target for the development of new anti-cancer drugs," said Cleveland, who has led numerous studies shedding light on this oncogene. "We are very hopeful that learning more about this process will open the door for the development of new treatments."

Specifically, the new project aims to define the mechanisms by which Myc controls the expression and function of Tristetraprolin or TTP, a mRNA-binding protein that normally controls the destruction of a subset of important mRNAs. Importantly, Research Associate Robert Rounbehler, PhD, and other colleagues in the Cleveland lab have shown that TTP functions as a tumor suppressor that impairs the development and maintenance of B lymphoma. Their findings indicating that agents that regulate TTP or affect its key mRNA targets hold great promise as anti-cancer agents.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert  

Related biology news :

1. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
2. Scientists identify novel inhibitor of human microRNA
3. Argonne scientists peer into heart of compound that may detect chemical, biological weapons
4. MU scientists go green with gold, distribute environmentally friendly nanoparticles
5. Scientists identify gene that may contribute to improved rice yield
6. Scientists discover why a mothers high-fat diet contributes to obesity in her children
7. MU scientists see how HIV matures into an infection
8. Earth scientists keep an eye on Texas
9. Thinking it through: Scientists call for policy to guide biofuels industry toward sustainability
10. Scientists identify a molecule that coordinates the movement of cells
11. Scientists Find new migratory patterns for Mediterranean and Western Atlantic bluefin tuna
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists win $2 million to study new pathway in development and maintenance of lymphoma
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... Ca (PRWEB) , ... August 16, 2017 , ... ... by changing into a different cell type. Many treatments for specific cancers, such ... prominent example of targeted treatment is androgen deprivation therapy for advanced prostate cancer. ...
(Date:8/16/2017)... Aug. 16, 2017  This year,s edition of the Inc. 5000 features ... sciences workforce solutions, has made the list for the third year in ... nation,s fastest-growing private companies based on a set of quantitative metrics. In ... the fastest-growing companies in the Bay State . ... Inc. 5000 ...
(Date:8/15/2017)... CA (PRWEB) , ... August 15, 2017 , ... ... pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of ... number of steps needed to gain kinetic binding data for a wide range ...
(Date:8/15/2017)... ... August 15, 2017 , ... The Conference Forum ... Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. The partnership ... 2018, at The Roosevelt Hotel in New York City. , “With our experience in ...
Breaking Biology Technology: